BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.
Recent data suggest that constitutional genetic variation in the antiapoptotic BCL2 gene could be associated with the susceptibility to develop chronic myeloid leukemia (CML) and the clinical outcome in several hematological malignancies. The present study examines whether BCL2 single nucleotide polymorphisms (SNPs) predispose to CML or may potentially influence the disease characteristics at diagnosis. Notably, no association was observed between the four candidate BCL2 SNPs and the risk of developing CML. Instead, the 4777C>A (rs2279115) and the 5735A>G (rs1801018) SNPs were significantly associated with the disease risk profile as determined by the Sokal score. We found that such polymorphisms correlated with the expression of BCL2 alternative splicing transcripts (BCL2-α, BCL2-β) in healthy donors, but not in CML patients, although the relative levels of BCL2 mRNA splicing variants were shown to change during the clinical course of CML. Our findings suggest that BCL2 polymorphisms could influence the clinical features of CML patients at diagnosis. However, the pathogenic mechanisms involved in such association remain to be ascertained.
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
Vicent
V
Guillem
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
Paula
P
Amat
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
María
M
Collado
Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain.
Francisco
F
Cervantes
Hematology Department, Hospital del Mar, IMIM, Barcelona, Spain.
Alberto
A
Alvarez-Larrán
Hematology Department, Hospital La Fe, Valencia, Spain.
Jesús
J
Martínez
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
Eduardo
E
Tormo
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain.
Pilar
P
Eroles
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain; Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
Carlos
C
Solano
Hematology and Medical Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, Valencia, Spain. Electronic address: hernandez_jca@gva.es.
Juan Carlos
JC
Hernández-Boluda
BCL2; Chronic myeloid leukemia; Polymorphisms; Splicing; Susceptibility